Bioxodes is a clinical-stage biopharmaceutical company focused on developing innovative therapies for thrombo-inflammatory and inflammatory diseases, particularly targeting hemorrhagic stroke. Their lead drug candidate, BIOX-101 (Ir-CPI), is designed to prevent thrombosis and neuroinflammation in patients suffering from intracerebral hemorrhage (ICH). This drug exhibits a unique mechanism of action by specifically targeting coagulation factors FXIIa and FXIa, as well as neutrophils, which are critical components in the neuroinflammatory process associated with ICH. Notably, BIOX-101 aims to prevent blood clot formation without increasing the risk of bleeding, a significant advantage for ICH patients. Currently, Bioxodes is conducting a Phase IIa clinical trial to assess the safety and initial efficacy of BIOX-101 in this patient population.

In addition to BIOX-101, Bioxodes is developing a broader pipeline of drug candidates aimed at addressing chronic thrombo-inflammatory and inflammatory conditions. The company leverages its expertise in understanding thrombo-inflammatory events to create novel therapies that achieve anticoagulation without the associated hemorrhagic risks. The active ingredient in BIOX-101 is derived from the saliva of ticks, which contains proteins that have been isolated and repurposed for therapeutic use. This innovative approach highlights Bioxodes' commitment to harnessing natural compounds for the development of breakthrough treatments, with the potential to significantly improve patient outcomes in the context of stroke and related conditions.

Belgium

Bioxodes is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of therapeutics for patients with thrombo-inflammatory diseases. We leverage our deep understanding of the thrombotic and inflammatory processes to design novel product candidates with an aim to address unmet medical needs.

Bioxodes

Company Details